Pacific Biosciences
PACB
226 hedge funds and large institutions have $395M invested in Pacific Biosciences in 2024 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 69 increasing their positions, 77 reducing their positions, and 25 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
19% more capital invested
Capital invested by funds: $332M → $395M (+$62.7M)
8% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 25
9% less call options, than puts
Call options by funds: $3.31M | Put options by funds: $3.63M
1% less funds holding
Funds holding: 229 → 226 (-3)
3.89% less ownership
Funds ownership: 88.98% → 85.1% (-3.9%)
10% less repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 77
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$9.52M |
| 2 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
+$5.87M |
| 3 |
Jane Street
New York
|
+$1.59M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.5M |
| 5 |
Morgan Stanley
New York
|
+$1.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$13.7M |
| 2 |
Bank of New York Mellon
New York
|
-$7.17M |
| 3 |
JSP
Jackson Square Partners
Larkspur,
California
|
-$4.25M |
| 4 |
D.E. Shaw & Co
New York
|
-$2.25M |
| 5 |
VS
VK Services
Menlo Park,
California
|
-$2.16M |
PACB Hedge Fund Activity: Q3 2024 in Review
226 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q3 2024, worth a combined $395M — up 19% from $332M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of PACB and 23 opened new positions — a net loss of 2 holders — while 77 trimmed existing stakes and 69 added.
The largest buyer was Millennium Management, adding an estimated $9.52M. The largest seller was Vanguard Group, cutting an estimated $13.7M.
- 226 institutional investors held Pacific Biosciences (PACB) as of Q3 2024, down from 229 in Q2 2024.
- Funds reported $395M of Pacific Biosciences stock for Q3 2024, up 19% quarter-over-quarter.
- 23 funds opened new Pacific Biosciences positions in Q3 2024 and 25 closed out, a net change of -2 holders.
- The largest Pacific Biosciences buyer in Q3 2024 was Millennium Management, an estimated $9.52M added.
- The largest Pacific Biosciences seller in Q3 2024 was Vanguard Group, an estimated $13.7M sold.
Based on aggregated 13F filings for Q3 2024.